Financials Deutsche Biotech Innovativ AG Deutsche Boerse AG
Equities
DBI
DE000A0Z25L1
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.05 EUR | -.--% | -.--% | -.--% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 66.31 | 66.78 | 85.26 | 74.36 | 82.89 | 25.39 |
Enterprise Value (EV) 1 | 66.17 | 66.64 | 85.14 | 74.33 | 82.87 | 25.38 |
P/E ratio | -261 x | -404 x | -211 x | - | -371 x | -107 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 303 x | 555 x | - | - | - | - |
EV / Revenue | 302 x | 554 x | - | - | - | - |
EV / EBITDA | -274 x | -414 x | -959 x | -200 x | -417 x | -3,019 x |
EV / FCF | -503 x | -894 x | 806 x | 146 x | 497 x | -61.2 x |
FCF Yield | -0.2% | -0.11% | 0.12% | 0.68% | 0.2% | -1.63% |
Price to Book | 31.6 x | 34.6 x | 55.9 x | - | 90.3 x | 37.3 x |
Nbr of stocks (in thousands) | 947 | 947 | 947 | 947 | 947 | 947 |
Reference price 2 | 70.00 | 70.50 | 90.00 | 78.50 | 87.50 | 26.80 |
Announcement Date | 5/2/18 | 6/28/19 | 8/13/20 | 6/5/23 | 6/5/23 | 6/5/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 0.2188 | 0.1204 | - | - | - | - |
EBITDA 1 | -0.2416 | -0.1611 | -0.0887 | -0.371 | -0.1985 | -0.008406 |
EBIT 1 | -0.2446 | -0.1641 | -0.0894 | -0.373 | -0.2015 | -0.1104 |
Operating Margin | -111.79% | -136.33% | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.254 | -0.1654 | -0.4045 | -0.385 | -0.2233 | -0.2364 |
Net income 1 | -0.254 | -0.1654 | -0.4045 | -0.385 | -0.2233 | -0.2364 |
Net margin | -116.08% | -137.39% | - | - | - | - |
EPS 2 | -0.2682 | -0.1746 | -0.4270 | - | -0.2357 | -0.2496 |
Free Cash Flow 1 | -0.1316 | -0.0745 | 0.1056 | 0.5091 | 0.1667 | -0.4146 |
FCF margin | -60.14% | -61.9% | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 5/2/18 | 6/28/19 | 8/13/20 | 6/5/23 | 6/5/23 | 6/5/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 0.14 | 0.14 | 0.11 | 0.03 | 0.02 | 0.01 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -0.13 | -0.07 | 0.11 | 0.51 | 0.17 | -0.41 |
ROE (net income / shareholders' equity) | -11.8% | -8.21% | -23.4% | -28.9% | -21.7% | -29.6% |
ROA (Net income/ Total Assets) | -6.82% | -4.67% | -2.69% | -11% | -5.54% | -3.12% |
Assets 1 | 3.723 | 3.538 | 15.01 | 3.497 | 4.032 | 7.574 |
Book Value Per Share 2 | 2.210 | 2.040 | 1.610 | - | 0.9700 | 0.7200 |
Cash Flow per Share 2 | 0.1500 | 0.1500 | 0.1200 | - | 0.0200 | 0.0100 |
Capex 1 | 0 | 0 | - | 0.01 | - | - |
Capex / Sales | 0.91% | 1.66% | - | - | - | - |
Announcement Date | 5/2/18 | 6/28/19 | 8/13/20 | 6/5/23 | 6/5/23 | 6/5/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- DBI Stock
- DBI Stock
- Financials Deutsche Biotech Innovativ AG